Related Experiment Video
Updated: Apr 19, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort
Abha G Singh1, Tanaz A Kermani1, Cynthia S Crowson1
1From the Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; Division of Rheumatology, University of California, Los Angeles; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.A.G. Singh, MBBS, Division of Rheumatology, Mayo Clinic; T.A. Kermani, MD, MS, Division of Rheumatology, University of California, Los Angeles; C.S. Crowson, MS, Division of Rheumatology, Mayo Clinic; C.M. Weyand, MD, PhD, Division of Immunology and Rheumatology, Stanford University School of Medicine; E.L. Matteson, MD, MPH; K.J. Warrington, MD, Division of Rheumatology, Mayo Clinic.
Objective:
To evaluate clinical characteristics, treatment, and outcomes of patients with visual changes from giant cell arteritis (GCA) and to examine trends over the last 5 decades.
Methods:
We reviewed the medical records of a population-based cohort of patients with GCA diagnosed between 1950 and 2004. The clinical, ophthalmological, and laboratory features of patients with visual manifestations attributable to GCA were compared to patients without visual complications. Trends over time were examined using logistic regression modeling adjusted for age and sex.
Results:
In a cohort of 204 cases of GCA (mean age 76.0 ± 8.2 yrs, 80% female), visual changes from GCA were observed in 47 patients (23%), and 4.4% suffered complete vision loss. A higher proportion of patients with visual manifestations reported jaw claudication than did patients without visual changes (55% vs 38%, p = 0.04). Over a period of 55 years, we observed a significant decline in the incidence of visual symptoms due to GCA. There was a lower incidence of ischemic optic neuropathy in the 1980-2004 cohort vs 1950-1979 (6% vs 15%, p = 0.03). Patients diagnosed in later decades were more likely to recover from visual symptoms (HR 1.34, 95% CI 1.06-1.71). Chances of recovery were poor in patients with anterior ischemic optic neuropathy or complete vision loss.
Conclusion:
Incidence of visual symptoms has declined over the past 5 decades, and chances of recovery from visual symptoms have improved. However, complete loss of vision is essentially irreversible. Jaw claudication is associated with higher likelihood of development of visual symptoms.
More Related Videos
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
10:24Detecting Abnormalities in Choroidal Vasculature in a Mouse Model of Age-related Macular Degeneration by Time-course Indocyanine Green Angiography
Published on: February 19, 2014
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Coronary Artery Disease III: Clinical Manifestations
Glaucoma: Overview